Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Immunovia Expands Application of Pancreatic Cancer Test in Swedish Diabetes Study

Immunovia Expands Application of Pancreatic Cancer Test in Swedish Diabetes Study

Jan 02, 2018
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) – Immunovia, a Swedish molecular diagnostics company, has initiated a new study with academic collaborators to diagnose early-stage pancreatic cancer in new onset diabetes patients.

Over the next three years, Immunovia and its partners will use the firm's Immray PanCan-d assay to screen 6,000 diabetes patients for pancreatic cancer. The study, called PanDIA-1, is in line with a Swedish government objective to introduce a national screening program for addressing diabetes comorbidities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Call to Expand

The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.

Additional Suit

The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.

Racism in Public Health

Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.

PNAS Studies Look at Inca Resettlement, Spermatogonial Stem Cell Transcriptomes, More

In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
22
Featured Webinar

Advances in Genetic Testing for IVF Research: PGT-A, PGT-M, and Carrier Screening

Sponsored by
Thermo Fisher Scientific

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Molecular Diagnostics

  1. Thermo Fisher Scientific, First Genetics to Develop NGS-Based Diagnostics in Russia

  2. Helix, San Diego County Partner on COVID-19 Molecular Testing

  3. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

  4. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  5. Vela Diagnostics Automated Coronavirus Test Gets CE-IVD Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.